Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO

'Nanofludics' Accelerates Antibody Discovery

Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.

Coronavirus Covid-19 Protection and Vaccine. Medical hand glove blue molding vial vaccine hypodermic needle syringe injection treatment.
Established antibody discovery firms have accelerated their pace - but companies like Berkeley Lights promise it can move even faster

The COVID-19 pandemic has created an unprecedented response from global biopharma, with the sector turning much of its firepower on repurposing existing drugs and discovering new ones at unheard of speeds.

Among the fastest to respond have been established biotech companies, such as Regeneron Pharmaceuticals Inc., Vir and AstraZeneca, who...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip